The U.S. Centers for Disease Control and Prevention is observing a lower rate of severe allergic reactions in people in the United States who have received Pfizer Inc. and BioNTech SE’s Covid-19 vaccine.
Severe allergic reactions to Moderna Inc.’s coronavirus vaccine appear to be quite rare, the U.S. Centers for Disease Control and Prevention (CDC) said, after more than 4 million people received their first dose.
Moderna Inc. received a report from California’s health department that several people at a center in San Diego were treated for possible allergic reactions to the company’s Covid-19 vaccine from a particular batch.
DBV Technologies unveiled a global restructuring plan that will result in a reduction of more than 200 jobs.
BioSpace reviewed the top 10 novel drug approvals of 2020, loosely based on projected earnings in the upcoming years.
The European Commission approved Aimmune Therapeutics Inc.’s Palforzia for the treatment of peanut allergy.
Top U.S. Food and Drug Administration regulators said most Americans with allergies should be safe to receive the Covid-19 vaccine developed by Pfizer Inc. and Germany’s Biotech SE.
The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted 17-4 to recommend Pfizer and BioNTech’s Covid-19 vaccine for Emergency Use Authorization (EUA) for individuals ages 16 years and older.
UK regulators stated that they received two reports of potential allergic reactions linked to the Covid-19 vaccine from Pfizer and BioNTech, according to the Associated Press.
Sociétés des Produits Nestlé, a part of Nestlé Health Science, acquired the outstanding shares of California-based Aimmune for $2.6 billion in cash following years of increasing its financial position in the food allergy-focused company.